In this large (n = 396), multicenter (n = 13 sites) retrospective chart review of patients with KRAS G12C mutant NSCLC we observed a relatively short median rwPFS of 4.6 months among patients with KRAS G12C mutant NSCLC treated with docetaxel with or without ramucirumab in the second-line setting, which aligns with the recently reported CodeBreak 200 dataset. This evidence concerns the gene KRAS and non-small cell lung carcinoma.